Five drug discovery companies have entered the BioInnovation Institute’s (BII) Venture Lab acceleration programme for early-stage companies as part of a cohort of ten new members. The 12-month Venture Lab programme is designed to support start-up companies with business acceleration, scientific, and team development, and provides a… Read More
Five Alarm Bio (FAB) has completed a seed investment round, raising over £500K ($605K). The funding will drive proprietary research into novel compounds that extend healthy lifespan of cells and tissues, with therapeutic potential across a broad range of age-related diseases. Investors include Cambridge Angels, Meltwind, o2h Ventures, and SyndicateRoom,… Read More
New kids on the block, Atomic AI, recently closed a $35 million series A financing. DDW’s Diana Spencer speaks to Raphael Townshend PhD, Founder and CEO of Atomic AI, about the company’s successes so far, plans for the future and the unique approach of combining RNA structural biology and AI… Read More
Aera Therapeutics has launched with a vision to “unlock the potential of genetic medicines across a wide range of modalities and therapeutic areas”. The company’s delivery platform is based on research conducted in the laboratory of scientific founder Feng Zhang and aims to address the limitations of… Read More
Stitch Health is a London-based start-up, on a mission to improve clinical trials by measuring and surfacing each patient’s experience. DDW’s Megan Thomas caught up with Jonathan Moshinsky, Co-Founder and CEO. MT: Near the end of 2022, Stitch closed £2.5 million seed funding to create the… Read More
Grey Wolf Therapeutics has closed an oversubscribed $49 million Series B financing co-led by Pfizer Ventures and Earlybird Venture Capital, with investment from Oxford Science Enterprises, British Patient Capital, Canaan and Andera Partners. Proceeds will support the continued development of the company’s first-of-its-kind immuno-oncology approaches designed to… Read More
Swedish start-up Atrogi has enrolled the first patient in its Phase Ia/b study of ATR-258, a novel b2adrenoceptor agonist for the treatment of type 2 diabetes and comorbidities. Conducted in Mannheim, Germany by Clinical Research Services (CRS), the trial is expected to be completed by April 2023… Read More
Listen to this article on the DDW Podcast: DDW Editor Reece Armstrong takes a look at Lithuania’s life sciences sector and what it means for start-ups operating in the country. A one to watch, would be my first thoughts when thinking about Lithuania and its start-up sector. After… Read More
Myosana Therapeutics has completed a seed funding round totalling over $5 million led by investor John Ballantyne. The capital will go towards developing Myosana’s gene therapy platform for neuromuscular and cardiac disease, with the goal of identifying the first development candidate for Duchenne muscular dystrophy by 2025. Read More
Atomic AI, a biotechnology company fusing machine learning with structural biology to unlock RNA drug discovery, launched today with a $35 million Series A round. The financing was led by Playground Global, with participation from 8VC, Factory HQ, Greylock, NotBoring, AME Cloud Ventures, and renowned angel investors… Read More
Tellus Therapeutics, a company developing treatments for newborns in the neonatal intensive care unit (NICU), announced the closing of a Series A financing round of $35 million led by the Perceptive Xontogeny Venture Fund. The capital will be used to continue preclinical work conducted through the seed… Read More
A project creating a new class of therapeutic proteins to modulate cell signalling has been accepted into the BioInnovation Institute (BII) Bio Studio programme. The project is based on recent breakthroughs in artificial intelligence (AI) and protein design, and uses methods pioneered by David Baker’s laboratory at the University of… Read More
Biotechnology company Infinimmune has closed a $12 million seed round to focus on human-derived antibody drugs. The seed funding was led by Playground Global, with participation from Pear VC, Civilization Ventures, Axial VC, Ron Alfa, Jacob Becraft, Paul Conley, and Joshua Meier. “The industry has proven the value of antibody-based… Read More
Neobe Therapeutics, an early-stage startup, has raised £520K ($628,000) in equity funding to engineer live biotherapeutics to remove barriers to immune infiltration in solid tumours. While immunotherapies have revolutionised the treatment of cancer, the large majority of patients with solid tumours (up to 85%) still do not… Read More
A new biotechnology company plans to pioneer the integrated mapping of disease networks for precision therapeutics. Rezo Therapeutics has launched with $78 million from a Series A financing, led by SR One, a16z Bio + Health, and Norwest Venture Partners. The company’s platform is based on technology from the Quantitative… Read More
Listen to this article on the DDW podcast: DDW Editor, Reece Armstrong, sits down with Brinter CEO Tomi Kalpio to learn about the company’s approach to bioprinting and how it can be used throughout drug discovery. Brinter is a provider of 3D… Read More
